Plaquenil for Alopecia Areata, Alopecia Totalis

Completed · Phase 4

Conditions studied: Alopecia Areata

In brief

Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). Published evidence says that it is mediated by T-lymphocytes. Plaquenil is an anti-inflammatory drug approved by the FDA for malaria, lupus erythematosus, and rheumatoid arthritis. It has an effect on T-lymphocyte mediated inflammation, making it a logical choice for a treatment trail for alopecia areata.

Key facts

Study ID
NCT00176982
Run by
Hordinsky, Maria K., MD
People needed
16
Starts
2002-04-01
Expected to finish
2008-01-01
Last updated by the study team
2009-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.